PMC

Validation of the physiologically based pharmacokinetic strategy against clinical data for an existing rilpivirine sustained-release formulation (600 mg; 100 mg/mL) []

Pharmacokinetics of monthly administration of antiretrovirals over a period of 6 months. a) Dolutegravir, b) Efavirenz, c) Emtricitabine, d) Raltegravir, e) Rilpivirine and f) Tenofovir

The whole body physiologically based pharmacokinetic model with an additional compartment for intramuscular depot and the blood capillaries surrounding the depot. Each of the arrows represents the flow kinetics assumed between tissues in the model. The small intestine is divided into seven parts for effective absorption kinetics. Metabolism occurs in the liver and intestine. Unabsorbed drug is excreted through faeces and excretion occurs through the kidneys. The green line represents the kinetics of the release from the nanoparticulate intramuscular depot. IM – intramuscular, RV and LV - right and left ventricle respectively.